COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marla C. Dubinsky  1     Keith A. Betts  2     Kenneth LaPensee  3     Lei Yin  3     Devrim Eren  3     Wenxi Tang  3     Komal Gupte-Singh  3    
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 Analysis Group, Inc., Los Angeles, United States
3 Bristol Myers Squibb Company, Princeton, United States

Session
Health economical aspect in GI disorders

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing